Related Experiment Videos
[Parkinson disease and the neuronal dopamine uptake complex]
1Unité de Neuropsychopharmacologie Expérimentale, C.N.R.S., Faculté de Médecine & Pharmacie de Rouen, Saint-Etienne-du-Rouvray.
Annales Pharmaceutiques Francaises
|January 1, 1995
Summary
The dopamine transporter (DAT) is crucial for regulating dopamine levels and may be a target for Parkinson's disease treatment. Inhibiting DAT could prevent neurodegeneration and alleviate associated symptoms.
Area of Science:
- Neuroscience
- Pharmacology
Context:
- The dopamine transporter (DAT) is vital for clearing synaptic dopamine.
- DAT is implicated in the neurodegenerative processes of Parkinson's disease.
- DAT's role in concentrating neurotoxins is a significant concern.
Purpose:
- To highlight the dopamine transporter as a therapeutic target for Parkinson's disease.
- To explore the potential of DAT inhibition in preventing neurodegeneration.
- To investigate DAT's role in neurotoxin accumulation.
Summary:
- The dopamine transporter is localized on dopaminergic neurons and regulates synaptic dopamine.
- Degeneration of nigro-striatal dopaminergic neurons, linked to Parkinson's disease, involves DAT.
- DAT may contribute to neurodegeneration by concentrating neurotoxins.
- In vivo labeling of DAT can detect early denervation before clinical symptoms.
- Inhibiting DAT could prevent neurotoxin accumulation, halting neurodegeneration.
- DAT inhibitors may also reduce motor and depressive symptoms associated with Parkinson's disease.
Impact:
- DAT imaging could enable early diagnosis of Parkinson's disease.
- Targeting DAT with inhibitors offers a potential strategy to halt or slow Parkinson's progression.
- Dopamine transporter inhibitors may provide symptomatic relief for Parkinson's patients.